|
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
Company Shifts Focus from R&D to Increased Resourcing of ECG Software Sales and Customer Support
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), today announced operations and sales team changes intended to drive inside-sales through upgrading the Company's medical software customers to the new Windows 7 compatible Global ECG Management System software (GEMS™ WIN) and the Company's cloud-based GlobalCardio™ 12 Lead ECG solution. CardioComm Solutions' release of GEMS™ WIN was in response to the recent termination of Microsoft support for Windows XP as of April 2014. The GEMS™ WIN software release allows for functional operation of GEMS™ on the Windows 7 Operating System.
"Since November of 2013 we have been working towards building out the Company's Toronto employee base by progressively transitioning resources from our Victoria office. Order fulfilment, customer support, operations management, programing resources for the GEMS™ WIN, GlobalCardio™, HeartCheck™ device sales and SMART Monitoring ECG services are now run from Toronto," said Mr. Simi Grosman, a member of the Board of Directors for CardioComm Solutions.
"Following completion of a six month strategy review of the U.S. ECG markets, we have initiated the first phase of GEMS™ WIN sales through the establishment of a dedicated inside sales team exclusively focused on our extensive global customer database of GEMS™ 3 users who are now undertaking Windows 7 systems conversions," reported Etienne Grima, the Company's CEO. "We recognize the contributions to this strategy's implementation by Daniel Pawlik, former VP of Sales, a process that our Toronto-based inside sales team will continue to deploy." Mr. Pawlik recently resigned from the CardioComm Solutions Board of Directors and his VP Sales position to transition into a new opportunity known to the Company.
CardioComm Solutions has also announced that Branislav Vasilijevic has recently joined the Company as Director of Software Engineering, replacing the Company's Victoria-based CTO position. Dr. Vasilijevic has 20 years of experience designing and developing software solutions to address complex system requirements primarily in the field of Intra-Operative Neurophysiological Monitoring. With this new appointment, CardioComm Solutions further consolidates its software development resources in the Toronto head office while the Victoria location will remain as an important satellite resource. The Company will make further announcements related to the addition of senior staff as well as new ECG software sales channels focused on the Canadian, U.S. and international markets in the near future.
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
